Annexin Pharmaceuticals AB (publ) (Q910) Stock Price & News

All values in SEK	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	7.05M	8.00M	7.92M	8.48M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2.35M	2.26M	2.90M	2.96M
Operating expense	9.40M	10.26M	10.82M	11.14M
Total operating expenses	9.40M	10.26M	10.82M	11.14M
Operating income	-9.40M	-10.26M	-10.82M	-11.14M
Other non operating income	-	-	-	1.00K
EBT including unusual items	-9.90M	-10.52M	-10.52M	-11.56M
EBT excluding unusual items	-9.90M	-10.52M	-10.52M	-11.56M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-288.00K
Net income	-9.90M	-10.52M	-10.52M	-11.56M
Net profit margin	-	-	-	-
Earnings per share	-	-	-	-
Interest and investment income	154.00K	231.00K	34.00K	-
Interest expense	-	-	-	-
Net interest expenses	154.00K	231.00K	34.00K	-
Depreciation and amortization charges	-	-	-	-
EBITDA	-9.35M	-10.21M	-10.77M	-11.10M
Gain or loss from assets sale	-	-	-	-

Finance